Francis Séguy

449 total citations
14 papers, 192 citations indexed

About

Francis Séguy is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Francis Séguy has authored 14 papers receiving a total of 192 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 9 papers in Hematology and 3 papers in Molecular Biology. Recurrent topics in Francis Séguy's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Acute Myeloid Leukemia Research (6 papers) and Hemoglobinopathies and Related Disorders (6 papers). Francis Séguy is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Acute Myeloid Leukemia Research (6 papers) and Hemoglobinopathies and Related Disorders (6 papers). Francis Séguy collaborates with scholars based in Italy, United States and France. Francis Séguy's co-authors include Robert Dantzer, Florence Crestani, George Pentheroudakis, R. Obach, Ramón Salazar, Maja J.A. de Jonge, Jaap Verweij, Chris Twelves, Hans Gelderblom and Stephen T. Oh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Francis Séguy

14 papers receiving 189 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francis Séguy Italy 5 52 52 37 34 28 14 192
Alison McColl United Kingdom 8 63 1.2× 42 0.8× 81 2.2× 17 0.5× 4 0.1× 11 265
Mohammad Z. Alzahrani Saudi Arabia 8 116 2.2× 18 0.3× 52 1.4× 45 1.3× 2 0.1× 8 445
Camila M. Yonamine Brazil 11 156 3.0× 19 0.4× 36 1.0× 44 1.3× 6 0.2× 22 296
Tanel Traks Estonia 12 96 1.8× 34 0.7× 36 1.0× 26 0.8× 2 0.1× 24 337
Paul Basil United States 7 105 2.0× 23 0.4× 70 1.9× 9 0.3× 5 0.2× 12 281
Apeksha Sahu India 7 116 2.2× 20 0.4× 9 0.2× 19 0.6× 5 0.2× 8 260
Chengyun Feng China 12 128 2.5× 7 0.1× 22 0.6× 21 0.6× 2 0.1× 16 410
Yuewen Chen China 8 95 1.8× 11 0.2× 13 0.4× 9 0.3× 6 0.2× 23 224
Vinayak Rayannavar United States 7 111 2.1× 26 0.5× 47 1.3× 35 1.0× 1 0.0× 9 267
Thomas Bajaj Germany 6 73 1.4× 50 1.0× 27 0.7× 13 0.4× 4 0.1× 10 171

Countries citing papers authored by Francis Séguy

Since Specialization
Citations

This map shows the geographic impact of Francis Séguy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis Séguy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis Séguy more than expected).

Fields of papers citing papers by Francis Séguy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis Séguy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis Séguy. The network helps show where Francis Séguy may publish in the future.

Co-authorship network of co-authors of Francis Séguy

This figure shows the co-authorship network connecting the top 25 collaborators of Francis Séguy. A scholar is included among the top collaborators of Francis Séguy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis Séguy. Francis Séguy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Simonelli, Matteo, et al.. (2024). 617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study. Annals of Oncology. 35. S495–S495. 3 indexed citations
2.
3.
Bose, Prithviraj, Sanjay Mohan, Stephen T. Oh, et al.. (2023). Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).. Journal of Clinical Oncology. 41(16_suppl). 7017–7017. 3 indexed citations
4.
5.
Mohan, Sanjay, Stephen T. Oh, Jean‐Jacques Kiladjian, et al.. (2023). Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis. Blood. 142(Supplement 1). 624–624. 3 indexed citations
6.
Watts, Justin M., Anthony M. Hunter, Alessandra Iurlo, et al.. (2022). INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study. Blood. 140(Supplement 1). 9696–9697. 1 indexed citations
7.
Mohan, Sanjay, Stephen T. Oh, Haris Ali, et al.. (2022). A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF). Blood. 140(Supplement 1). 3943–3944. 3 indexed citations
8.
9.
Oh, Stephen T., Jean‐Jacques Kiladjian, Francesca Palandri, et al.. (2021). Abstract CT216: A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). Cancer Research. 81(13_Supplement). CT216–CT216. 1 indexed citations
10.
Oh, Stephen T., Jason Gotlib, Sanjay Mohan, et al.. (2020). A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). Blood. 136(Supplement 1). 3–3. 5 indexed citations
11.
12.
13.
Gelderblom, Hans, Ramón Salazar, Jaap Verweij, et al.. (2003). Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.. PubMed. 9(11). 4101–7. 32 indexed citations
14.
Crestani, Florence, Francis Séguy, & Robert Dantzer. (1991). Behavioural effects of peripherally injected interleukin-1: role of prostaglandins. Brain Research. 542(2). 330–335. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alison McColl Breakdown of academic impact, for papers by Mohammad Z. Alzahrani Breakdown of academic impact, for papers by Camila M. Yonamine Breakdown of academic impact, for papers by Tanel Traks Breakdown of academic impact, for papers by Paul Basil Breakdown of academic impact, for papers by Apeksha Sahu Breakdown of academic impact, for papers by Chengyun Feng Breakdown of academic impact, for papers by Yuewen Chen Breakdown of academic impact, for papers by Vinayak Rayannavar Breakdown of academic impact, for papers by Thomas Bajaj
Rankless by CCL
2026